## **REMARKS**

The advice about the Information Disclosure Statement is noted.

The forgoing amendments to the specification are made to amend the reference to the priority application, and to insert the required SEQ ID NO identifiers in the paragraph relating to Figure 2 on page 6.

The sole claim in the case Is Claim 92. This claim relates to the molecule which is described and enabled in the specification, and which was elected for prosecution. No prior art has been applied in a rejection against this subject matter. The rejections under Section 112 have been overcome by including language that meets the Section 112 requirements, MPEP 2163.

Favorable reconsideration of the application as amended is respectfully requested.

Respectfully submitted,

Date May 13, 2005

By

/Hesna J. Pfeiffer/

**JOHNSON & JOHNSON** 

One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 Telephone: 732-524-2830

Facsimile: 732-524-3591

Hesna J. Pfeiffer Attorney for Applicant Registration No. 22,640



Application of: Masure et al.	Docket No. JAB-1512 By: CATO
THE FOLLOWING HAS BEEN RECEIVED IN THE U.S. PATENT OFFICE ON THE DATE STAMPED HEREON	
THE FOLLOWING HAS BEEN RESERVED IN THE SISTEMATICAL STREET	
☐ Oath or Declaration	☐ Drawings sheets
☐ Assignment	☐ MPEP 609/
Response	☐ Notice of Appeal
☐ Fee Transmittal	☐ Brief
Charge to Deposit Account 10-0750	☐ Priority Document
Amendment and flashing for the Extension of Time Harmonian Liquid	ence Status Inquiry
□ Extension of Time PLANCE IN THE	☐ Sequence Listings/Diskette
☐ Issue Fee Transmittal	☐ Biological Deposit Declaration
PCT Filing	☐ Other
□ IDS-Form 1449	